Throne’s Stem Cell Educator Therapy is designed to reverse the root causes of autoimmune diseases, such as diabetes and alopecia atreata, by fundamentally “resetting” the immune system through a one-time dialysis-like treatment using CB-SC stem cells.
Stem Cell Educator Therapy is recognized as the leading “Practical Cure Project” for type 1 diabetes among 590 global technologies (JDCA State of the Cure 2021).
Fifteen years of clinical studies in the United States, China, Spain, and have demonstrated the clinical safety and efficacy of Stem Cell Educator Therapy in over 500 patients aged 3-86 years old. Throne is on track to commercialize this ready-to-use technology through the US FDA-approved Regenerative Medicine Advanced Therapy (RMAT) designation in April 24, 2024, and three FDA phase 2/3 approvals for the treatment of type 1 diabetes, alopecia areata, and COVID-19.
CEO and President
Dr. Zhao is an internationally acclaimed scientist and doctor who specializes in clinical immunology and stem cell biology, and received his post-doctoral training from the University of Chicago.
He is the first scientist to discover the cord blood stem cells (CB-SC) and is the inventor of Stem Cell Educator Therapy.
He has held academic and professorship positions at the University of Illinois at Chicago and Hackensack Meridian Health. He holds 12 patents and 63 publications.
Stem Cell Educator Therapy (or “Educator Therapy” for short) is an ex vivo process in which the patient’s white blood cells are collected and educated inside the Stem Cell Educator device coated with cord blood stem cells (CB-SC). During this treatment, the patient’s white blood cells interact with the CB-SC and are re-educated back to their pre-disease state. After the treatment for overnight, CB-SC-“educated” white blood cells (designated Gleukocell™) are returned to the patient’s circulation through infusion.
The newly educated white blood cells then continue the immune reset by training other defective immune cells in the patient’s body—teaching them whom to fight and whom to protect. This “immune reset” is designed to be minimally invasive, have virtually no side effects, and produce long-term results.
Throne aims to commercially launch its Stem Cell Educator Therapy once it receives regulatory approval.
In 2005, Dr. Yong Zhao discovered and patented a new type of stem cell from human umbilical cord blood called CB-SC. These ethically derived stem cells are more powerful than any other previously discovered multi-potent stem cells due to their “immune educating abilities”. CB-SC have the capability to correct autoimmunity, restore immune balance, and completely eliminate the requirement for stem cell genetic matching because of their low immunogenicity.
Using this new discovery, the Stem Cell Educator was invented to harness the immune modulating power of the CB-SC for clinical application.
Stem Cell Educator Therapy is the only technology in the world that is licensed to use this stem cell. Educator Therapy does NOT use other stem cells like embryonic stem cells (ESC), iPSC, MSC, or HSC.
Type 1 diabetes (T1D) is an autoimmune disease that causes a deficit of islet beta cells. Insulin injections are not a cure. Stem Cell Educator Therapy aims to fundamentally correct the autoimmune destructions of islet beta cells and their nerve systems, and improve the beta cell function. Over the last 15 years, Stem Cell Educator therapy has been evaluated through international multi-center clinical studies in the United States, China and Spain, which have demonstrated its clinical safety and efficacy in T1D.
Long COVID, generally defined as persisting clinical symptoms for 3 months or longer following the SARS-CoV-2 infection, affects multiple organs/systems and shares key features with autoimmune diseases. Similar to the principle mechanisms in treating subjects with multiple autoimmune diseases, Stem Cell Educator Therapy aims to reset and strengthen the impaired immune systems and thereby demonstrate the therapeutic efficacy of Stem Cell Educator therapy in alleviating long COVID symptoms and restoring immune balance for patients with long COVID.
Alopecia Areata is a common autoimmune disease that causes varying degrees of hair loss across the body. Current immunosuppressive treatments, such as steroid and JAK inhibitors, can only temporarily suppress the autoimmunity and regrow hairs, with side effects. Stem Cell Educator therapy could fundamentally restore the immune privilege of hair follicles and address multiple immune dysfunctions, leading to hair regrowth.
Systemic lupus erythematosus (SLE, Lupus) is a devastating autoimmune disease caused by the complex immune dysregulation, resulting in body’s immune system attacks patient’s own tissues and organs with substantial morbidity and mortality. Current clinical managements are to achieve disease remission or a state of low activity through the immune suppression and/or biologics, and thereby improve the patient’s quality of life.
Educator Therapy is not yet commercially available. We are currently undergoing the FDA approval process. We could offer the therapy if you and your child meet the criteria of FDA-approved Throne’s clinical trials. Alternatively, you and your child may receive Stem Cell Educator therapy via the Right-to-Try Act for patients with serious or life-threatening diseases.
The Right to Try (RTT) Act is one way for patients who have been diagnosed with life-threatening or serious diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain investigational treatment options. Throne could offer Stem Cell Educator Therapy through the RTT program for patients.
Stem Cell Educator Therapy utilizes an ex vivo method, ensuring immune acceptance and eliminating risks of rejection. Stem cells CB-SC are coated within the Stem Cell EducatorTM device, maximizing the immune education of patient's white blood cells (immune cells) and clinical efficacy after infusion of the educated patient’s own immune cells (GleukocellTM).
Many stem cell therapies use stem cells derived from animals or aborted fetuses, which can pose safety risks as well as ethical and religious concerns. Stem Cell Educator Therapy eliminates these issues, thereby opening many markets traditionally closed to stem cell therapies.
Stem Cell Educator Therapy is a minimally invasive treatment performed outside the patient’s body. Clinical trials demonstrate that this therapy has minimal to negligible side effects.
Stem Cell Educator Therapy is the only technology in the world that uses CB-SC, which are more powerful than any other stem cells in their immune-modulating abilities. They can correct autoimmunity, restore immune balance, and eliminate the need for stem cell genetic matching.
Over 25 years of research and more than 60 peer-reviewed journal publications document the ongoing development and scientific findings related to the molecular and cellular mechanisms underlying the Stem Cell Educator Therapy.
